Correlation of endogenous hormonal levels, fibroglandular tissue volume and percent density measured using 3D MRI during one menstrual cycle.

BACKGROUND We measured breast density (BD) on MRI and correlated with endogenous hormonal levels. PATIENTS AND METHODS Twenty-four premenopausal women received four weekly breast MRI. A blood sample was collected on the same day of MRI. BD was measured using a computer-based algorithm. The generalized estimation equation method was applied to model mean fibroglandular tissue volume (FV) and mean percent density (PD) from predictor variables including estradiol, progesterone, and week during a cycle. RESULTS In week 3, a borderline significant correlation between estradiol and PD (r = 0.43, P = 0.04), estradiol and FV (r = 0.40, P = 0.05) and between progesterone and FV (r = 0.42, P = 0.04) was noted. The FV and PD measured in weeks 4 and 1 were higher than in weeks 2 and 3, adjusted for variation in endogenous estradiol and progesterone, indicating that the hormone change could not account for the changes in density. No lag effect of endogenous hormone on the change of FV or PD was noted (all P-values > 0.05). CONCLUSIONS Our results showed that BD is not strongly associated with the endogenous hormone. Their association with breast cancer risk was likely coming from different mechanisms, and they should be considered as independent risk factors.

[1]  A. Jakobsen,et al.  A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  S. Feig,et al.  Menstrual cycle-related fluctuations in breast density measured by using three-dimensional MR imaging. , 2011, Radiology.

[3]  Bernard Rosner,et al.  Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics. , 2011, Journal of the National Cancer Institute.

[4]  Hein Putter,et al.  Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial , 2011, The Lancet.

[5]  O. Nalcioglu,et al.  A new bias field correction method combining N3 and FCM for improved segmentation of breast density on MRI. , 2010, Medical physics.

[6]  P. Lønning The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Catherine Klifa,et al.  Magnetic resonance imaging for secondary assessment of breast density in a high-risk cohort. , 2010, Magnetic resonance imaging.

[8]  Scott Devine,et al.  Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer , 2010, Breast Cancer Research and Treatment.

[9]  A. Rademaker,et al.  A prospective study of variability in mammographic density during the menstrual cycle , 2010, Breast Cancer Research and Treatment.

[10]  Michael Khazen,et al.  Assessing the usefulness of a novel MRI-based breast density estimation algorithm in a cohort of women at high genetic risk of breast cancer: the UK MARIBS study , 2009, Breast Cancer Research.

[11]  V. McCormack,et al.  Premenopausal mammographic density in relation to cyclic variations in endogenous sex hormone levels, prolactin, and insulin-like growth factors. , 2009, Cancer research.

[12]  N. Boyd,et al.  Differences in Measured Mammographic Density in the Menstrual Cycle , 2009, Cancer Epidemiology Biomarkers & Prevention.

[13]  K. Newton,et al.  Associations between endogenous sex hormone levels and mammographic and bone densities in premenopausal women , 2006, Cancer Causes & Control.

[14]  Michael Khazen,et al.  A Pilot Study of Compositional Analysis of the Breast and Estimation of Breast Mammographic Density Using Three-Dimensional T1-Weighted Magnetic Resonance Imaging , 2008, Cancer Epidemiology Biomarkers & Prevention.

[15]  Sheila Prindiville,et al.  Effect of Raloxifene on Mammographic Density and Breast Magnetic Resonance Imaging in Premenopausal Women at Increased Risk for Breast Cancer , 2008, Cancer Epidemiology Biomarkers & Prevention.

[16]  Min-Ying Su,et al.  Development of a quantitative method for analysis of breast density based on three-dimensional breast MRI. , 2008, Medical physics.

[17]  T. Whelan,et al.  The feasibility and responsiveness of the health utilities index in patients with early-stage breast cancer: A prospective longitudinal study , 2008, Quality of Life Research.

[18]  K. Chao,et al.  Standard and low-dose hormone therapy for postmenopausal women--focus on the breast. , 2007, Taiwanese journal of obstetrics & gynecology.

[19]  S. Cummings,et al.  Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. , 2007, Endocrine-related cancer.

[20]  N. Boyd,et al.  Mammographic density and the risk and detection of breast cancer. , 2007, The New England journal of medicine.

[21]  V. Shane Pankratz,et al.  Mammographic Breast Density as a General Marker of Breast Cancer Risk , 2007, Cancer Epidemiology Biomarkers & Prevention.

[22]  R. Chlebowski,et al.  Adherence to Endocrine Therapy for Breast Cancer , 2007, Oncology.

[23]  D. Miglioretti,et al.  Mammographic Breast Density, Dense Area, and Breast Area Differences by Phase in the Menstrual Cycle , 2006, Cancer Epidemiology Biomarkers & Prevention.

[24]  Anna Chiarelli,et al.  Body Size, Mammographic Density, and Breast Cancer Risk , 2006, Cancer Epidemiology Biomarkers & Prevention.

[25]  D. Spiegelman,et al.  Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. , 2006, Journal of the National Cancer Institute.

[26]  J. Cline,et al.  Effects of soy on the mammary glands of premenopausal female monkeys. , 2006, Fertility and sterility.

[27]  G. Maskarinec,et al.  Mammographic densities and circulating hormones: a cross-sectional study in premenopausal women. , 2006, Breast.

[28]  M. Stockler,et al.  Patients' preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile? , 2005, British Journal of Cancer.

[29]  Daniel B Kopans,et al.  Physiologic Changes in Breast Magnetic Resonance Imaging during the Menstrual Cycle: Perfusion Imaging, Signal Enhancement, and Influence of the T1 Relaxation Time of Breast Tissue , 2005, The breast journal.

[30]  J. Stines,et al.  The normal breast and its variations in mammography. , 2005, European journal of radiology.

[31]  P. Muti The role of endogenous hormones in the etiology and prevention of breast cancer: the epidemiological evidence. , 2005, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[32]  Berkman Sahiner,et al.  Correlation between mammographic density and volumetric fibroglandular tissue estimated on breast MR images. , 2004, Medical physics.

[33]  Karla Kerlikowske,et al.  Mammographic breast density and family history of breast cancer. , 2003, Journal of the National Cancer Institute.

[34]  G. Adam,et al.  MR-Mammographie bei 0,5 Tesla: Menstruationszyklusabhängigkeit der Kontrastmittelanreicherung unter hormoneller Kontrazeption? , 2003 .

[35]  G. Adam,et al.  [MR-imaging of the breast at 0.5 Tesla: menstrual-cycle dependency of parenchymal contrast enhancement in healthy volunteers with oral contraceptive use?]. , 2003, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

[36]  Seema A. Khan,et al.  Morphological Changes in Breast Tissue with Menstrual Cycle , 2002, Modern Pathology.

[37]  Celine M Vachon,et al.  Case-control study of increased mammographic breast density response to hormone replacement therapy. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[38]  N F Boyd,et al.  The association of breast mitogens with mammographic densities , 2002, British Journal of Cancer.

[39]  W. Rakowski,et al.  Adjuvant tamoxifen prescription in women 65 years and older with primary breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  G C McKinnon,et al.  Menstrual cycle variation of apparent diffusion coefficients measured in the normal breast using MRI , 2001, Journal of magnetic resonance imaging : JMRI.

[41]  S. Jansen,et al.  Stability of Patients’ Preferences for Chemotherapy , 2001, Medical decision making : an international journal of the Society for Medical Decision Making.

[42]  M. Pike,et al.  Mammographic density changes during the menstrual cycle. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[43]  N Roberts,et al.  Estimation of breast volume and its variation during the menstrual cycle using MRI and stereology. , 1999, The British journal of radiology.

[44]  J. Weinman,et al.  The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication , 1999 .

[45]  E. Merkle,et al.  MR mammography: influence of menstrual cycle on the dynamic contrast enhancement of fibrocystic disease , 1999, European Radiology.

[46]  E White,et al.  Variation in mammographic breast density by time in menstrual cycle among women aged 40-49 years. , 1998, Journal of the National Cancer Institute.

[47]  P. Ravdin,et al.  Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  C. Claussen,et al.  Menstrual cycle and age: influence on parenchymal contrast medium enhancement in MR imaging of the breast. , 1997, Radiology.

[49]  S. J. Graham,et al.  Quantitative correlation of breast tissue parameters using magnetic resonance and X-ray mammography. , 1996, British Journal of Cancer.

[50]  D B Plewes,et al.  Changes in fibroglandular volume and water content of breast tissue during the menstrual cycle observed by MR imaging at 1.5 t , 1995, Journal of magnetic resonance imaging : JMRI.

[51]  M. Pike,et al.  Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. , 1993, Epidemiologic reviews.

[52]  L. Bernstein,et al.  Endogenous hormones and breast cancer risk. , 1993, Epidemiologic reviews.

[53]  Horton,et al.  Annals of Oncology , 1991, Springer US.

[54]  P A Fowler,et al.  Cyclic changes in composition and volume of the breast during the menstrual cycle, measured by magnetic resonance imaging , 1990, British journal of obstetrics and gynaecology.

[55]  M. Pike,et al.  The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. , 1988, European journal of cancer & clinical oncology.

[56]  A. Morrison,et al.  Endogenous sex hormones, prolactin, and mammographic features of breast tissue in premenopausal women. , 1986, Journal of the National Cancer Institute.

[57]  T. Longacre,et al.  A Correlative Morphologic Study of Human Breast and Endometrium in the Menstrual Cycle , 1986, The American journal of surgical pathology.

[58]  D. G. Hoel,et al.  ‘Hormonal’ risk factors, ‘breast tissue age’ and the age-incidence of breast cancer , 1983, Nature.

[59]  F. Vogel,et al.  The correlation of histologic changes in the human breast with the menstrual cycle. , 1981, The American journal of pathology.

[60]  S. Holm A Simple Sequentially Rejective Multiple Test Procedure , 1979 .